Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

IRA Impacts: Cancer treatment research and development

By Andrew Powaleny  |    March 23, 2023
Last month marked the one-year anniversary of the reignited Cancer Moonshot, the White House’s ambitious goal of reducing the death rate from cancer by at least 50% over the next 25 years. Much of...   Read More

Celebrating 40 years of the Orphan Drug Act on Rare Disease Day

By Abigail Lore  |    February 28, 2023
For over a decade, Rare Disease Day has been celebrated on February 28 to raise awareness and generate change for the more than 30 million patients in the U.S. living with a rare disease. This year’s...   Read More

WTAS: Inflation Reduction Act already impacting R&D decisions

By Nicole Longo  |    January 17, 2023
The Inflation Reduction Act’s (IRA’s) drug price setting provisions, as predicted, are already impacting biopharmaceutical research & development (R&D) decisions. Whether you are looking at estimates...   Read More

ICYMI: PhRMA COO Lori Reilly speaks about the health care agenda for the next Congress

By Lori Reilly  |    December 9, 2022
With a divided Congress, bipartisan action will be necessary to move the needle on health care policy. On December 7, 2022, PhRMA sponsored the Axios event, “The Post-Midterm Health Care Agenda,”...   Read More

New government price setting policy threatens post-approval research

By Nicole Longo  |    November 10, 2022
Have you ever noticed that one medicine might be used to treat two, three, seven different conditions? That’s the result of significant additional research and investment, including lengthy and...   Read More

Rejecting ICER’s bad advice

By Priscilla VanderVeer  |    September 9, 2022
America leads the world in biomedical innovation today because our system rewards investment in research and discovery of new treatments. Now, with the passage of the Inflation Reduction Act, Dr....   Read More

New survey: Voters seriously concerned about fine print in reconciliation bill

By Mark Keida  |    August 12, 2022
With a final vote in Congress expected on a reconciliation spending bill, a new Morning Consult survey explores what this legislation actually does – and does not do – and finds that voters are...   Read More

This week’s reading list: All the reasons the Senate-passed drug pricing bill is bad policy

By Nicole Longo  |    August 10, 2022
Last weekend, the Senate passed the Inflation Reduction Act which includes dangerous price-setting provisions. The bill now heads to the House for consideration, where it is not too late for them to...   Read More

Myth vs. Fact: The Senate’s latest price setting proposal

By Nicole Longo  |    August 5, 2022
The narratives being built around the Senate’s latest price setting proposal frame it as a bill intended to lower drug prices for patients and address rising inflation. But those narratives aren’t...   Read More

An open letter to Congress: Stand with patients and future cures

By Stephen J. Ubl  |    August 4, 2022
I recently joined PhRMA board members in penning the letter below to Congress, urging them to abandon their latest drug pricing proposal. You can read the letter here or below:   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates